Androgenetic alopecia is the most common hair loss disorder, affecting both men and women. Initial signs of androgenetic alopecia usually develop during teenage years leading to progressive hair loss with a pattern distribution. Moreover, its frequency increases with age and affects up to 80% Caucasian men and 42% of women. Patients afflicted with androgenetic alopecia may undergo significant impairment of quality of life. The European Dermatology Forum (EDF) initiated a project to develop evidence-based guidelines for the treatment of androgenetic alopecia. Based on a systematic literature research the efficacy of the currently available therapeutic options was assessed and therapeutic recommendations were passed in a consensus conference.

The purpose of the guideline is to provide dermatologists with an evidence-based tool for choosing an efficacious and safe therapy for patients with androgenetic alopecia.

雄激素性脱发是最常见的脱发疾病，影响男性和女性。雄激素性脱发的最初体征通常在青少年时期出现，导致进行性脱发，呈模式分布。此外，其频率随年龄增长而增加，影响高达80%的高加索男性和42%的女性。受雄激素性脱发困扰的患者可能会出现生活质量的显著损害。欧洲皮肤病论坛 (EDF) 启动了一个项目，制定基于证据的雄激素性脱发治疗指南。基于一项系统性文献研究，对现有治疗选择的疗效进行了评估，并在共识会议上通过了治疗建议。

该指南的目的是为皮肤科医生提供一种基于证据的工具，为雄激素性脱发患者选择一种有效且安全的疗法。